Trulieve has become the first US cannabis company with direct operations in the industry to list on the New York Stock Exchange, under the ticker TRLV. The listing is being seen as a historic step for the US cannabis industry, which has long been confined to smaller trading venues even as the market has grown sharply across several states.
Trulieve opens the door to a larger stock market
Companies that grow or sell cannabis in the United States have long struggled to gain access to the country’s largest stock exchanges. Trulieve’s arrival on the NYSE therefore marks a clear shift, giving the company access to a more liquid market and a broader investor base than had previously been possible.
The stock initially rose after the listing, showing that the market is watching developments closely. At the same time, it remains to be seen how trading will develop over the longer term and whether investors view the sector as a more stable option than before.
Get the week’s important news from Cannabis.se in your inbox — interesting weekend reading! 🥦✉️
Federal rescheduling has changed the playing field for cannabis companies
Behind the listing is the federal policy shift that has made it easier for medical cannabis companies to move closer to major US stock exchanges. When medical cannabis was moved from Schedule I to Schedule III, a new opportunity opened up for companies that had previously been shut out of the biggest trading venues.
The development is being watched closely because it could matter for the entire US cannabis industry. An upcoming DEA hearing is also expected to provide further signals about how regulation may develop going forward.
Trulieve’s medical business became its path onto the NYSE
According to the reporting, Trulieve reached the listing by separating its medical assets from its recreational business. That structure is said to have made it possible to meet the exchange’s requirements.
The company’s strong position in Florida has also played an important role. Trulieve holds a significant share of the state’s medical cannabis market, making the medical business a major asset even on its own.
The listing could become important for the rest of the US cannabis industry
Trulieve’s listing is now expected to send a signal to both investors and other cannabis companies in the United States. If trading remains stable, it could strengthen the case for more US cannabis companies to try to reach the NYSE or Nasdaq.
At the same time, uncertainty around the sector remains. Rules still differ between the federal level and the states, and investors are likely to weigh both political risks and company profitability before more similar listings become realistic.
Source
Trulieve Makes History as the First US Cannabis Company to Trade on the NYSE
Sponsor: Sensi Seeds are one of Europe’s most recognized names in premium cannabis genetics, offering a wide selection of feminized, autoflowering, CBD-rich and F1 hybrid seeds for customers who want quality, consistency and choice.